EVALUASI POLA PERESEPAN & PENGARUH RASIONALITAS ANTIBIOTIK PROFILAKSIS TERHADAP KEJADIAN INFEKSI DAERAH OPERASI PADA PASIEN BEDAH ANAK

Evaluation of Prescribing Patterns & Influence of Rationality of Prophylactic Antibiotics on the Incidence of Surgical Site Infections in Pediatric Surgery Patients

Abstract

Surgical area infections (IDOs) are one of the most commonly found healthcare-related infections, with an incidence of up to one in 3 patients undergoing surgery. The administration of antibiotics needs to be done rationally to maximize efficacy and prevent the development of antimicrobial resistance. Research related to IDOs in pediatric surgical patients will be able to help policymakers to determine the most effective measures in the prevention of IDO. This study is an analytical observational study with a retrospective cohort design, which involves the medical records of pediatric patients undergoing invasive surgical procedures in the period from July 1 to December 31, 2023 at Prof. Dr. R. Soeharso Orthopedic Hospital Surakarta. The variables observed in this study were the rationality of prophylactic antibiotic therapy given to pediatric surgery patients, and clinical outcomes in the form of IDO incidence. The rationality of prophylactic antibiotics was assessed using the Gyssens algorithm, referring to the series of IDO prevention procedures published by the POP-NeoPed Study Group and the administration of prophylactic antibiotics by the American Society of Health-System Pharmacists (ASHP). Clinical outcomes in the form of IDO incidence are determined by criteria compiled by the CDC. Data from 268 prophylactic antibiotic therapies in pediatric surgical patients, there were 33 therapies (12.31%) that were included in category VI (incomplete data), 94 therapies (35.07%) that were included in category V (no indication of antibiotic administration), 2 therapies (0.75%) that were included in category IVd (there are other antibiotics with a narrower spectrum), 125 therapies (46.64%) that were included in category IIa (inappropriate dose),  and 14 therapies (5.22%) that were included in category I (not timely administration).